Affymetrix Promotes Kevin King to Company President

Affymetrix Inc. (Nasdaq:AFFX) announced today that it has promoted Kevin M. King to president of the company, reporting to Stephen P.A. Fodor, Ph.D., chairman and CEO. King previously served as president of the life sciences business and executive vice president. "Since joining the company in January 2007, Kevin has helped refocus our life sciences business. Under his leadership, we have rebuilt our executive leadership team, defined our longer-term growth strategy and strengthened our market position by successfully launching the SNP Array 6.0 ahead of schedule,” said Fodor. "In his new position, Kevin will also assume responsibility for the Molecular Diagnostics business unit. I look forward to Kevin’s leadership, as we continue to accelerate our business through the commercialization of our innovations, strengthen the talent within the company and exceed our customers’ expectations.” Prior to joining Affymetrix, King worked at Thomson Corporation, where he served as president and CEO of Thomson Healthcare, the $500 million healthcare and pharmaceutical information services division of Thomson Corporation. At Thomson Healthcare, King was responsible for developing and implementing the growth strategy that led to its industry-leading position within the $7 billion healthcare decision support market. King has also held senior executive positions at General Electric Healthcare, including vice president and general manager, Global Clinical Systems. In that position, he grew the business to more than $900 million in revenue through the global sales distribution expansion, introduction of new technologies and strategic acquisitions. In addition, King brings more than 14 years of experience at Hewlett-Packard, where his many accomplishments included the creation of a web-enabled systems strategy to help speed the drug discovery process and reduce the time to complete clinical trials. "Affymetrix microarray technology has quickly become the Gold standard tool for life sciences, molecular diagnostic and consumer genetic applications,” said King. "The latest generation of Affymetrix arrays is enabling our customers to identify the genetic causes of complex diseases, such as Alzheimer’s, Parkinson’s and different types of cancers, in order to bring a more personalized form of healthcare to people around the world.” About Affymetrix Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,600 systems have been shipped around the world and more than 9,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com. Forward-looking Statements All statements in this press release that are not historical are "forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ "expectations,” "beliefs,” "hopes,” "intentions,” "strategies” or the like. These include statements related to the value of Kevin King’s experience and expertise to Affymetrix, which are prospective. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the management changes discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.